LY3372689

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Alzheimer DiseaseHealthy

Phase 1

A Safety Study of LY3372689 Given By Mouth to Healthy Participants

CompletedNCT03819270

Eli Lilly and CompanyHealthy

Start: 2019-02-05End: 2019-06-24Updated: 2019-07-05

A Study of the Effects of LY3372689 on the Brain in Healthy Participants

CompletedNCT03944031

Eli Lilly and CompanyHealthy

Start: 2019-05-08End: 2020-02-19Updated: 2020-04-22

A Safety Study of LY3372689 in Healthy Participants

CompletedNCT04106206

Eli Lilly and CompanyHealthy

Start: 2019-10-23End: 2020-02-12Updated: 2020-04-24

A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants

CompletedNCT04392271

Eli Lilly and CompanyHealthy

Start: 2020-08-06End: 2020-10-14Updated: 2020-11-04

Phase 2

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

CompletedNCT05063539

Eli Lilly and CompanyAlzheimer Disease

Start: 2021-09-16End: 2025-05-22Updated: 2026-06-12

Related Papers

Ceperognastat in Early Symptomatic Alzheimer Disease

JAMA2026-07-131 citations

Evaluation of Baseline Diffusion Tensor Imaging Biomarkers in phase 2 multi‐center PROSPECT‐ALZ study

Alzheimer s & Dementia2024-12-011 citations

Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers

Alzheimer s & Dementia2021-12-018 citations

Single and multiple ascending dose studies in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme

Alzheimer s & Dementia2021-12-016 citations

Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human

Alzheimer s & Dementia2020-12-0119 citations

A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme

Alzheimer s & Dementia2020-12-0111 citations